You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 24, 2024

Claims for Patent: 9,707,272

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 9,707,272

Title:	Method for the treatment of acne by administering IL-1.beta. antibody
Abstract:	The invention provides inhibitors capable of binding to a member of the inflammasome group comprised of IL-1.beta., IL-1 receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B with a dissociation constant of 10-8 mol/l or smaller for the prevention and treatment of acne, specifically an antibody, an antibody fragment, an antibody-like molecule, an oligopeptide of 6 to 30 amino acid residues, a nucleic acid aptamer molecule of 10 to 75 nucleotides in length or a soluble polypeptide comprising a contiguous amino acid sequence of at least 30 amino acids comprised within the protein sequence of a member of the group comprised of IL-1.beta., IL-1 receptor type 1, IL-1 receptor type 2, NLRP3, ASC and Caspase-1. Similarly, an interfering RNA or an antisense modulator of gene expression of IL-1.beta., I L-1.beta. receptor type 1, NLRP3, ASC, Caspase-1 and cathepsin B are provided for the prevention or treatment of acne.
Inventor(s):	Jankovic; Dragana (Basel, CH), Kistowska; Magdalena (Dietikon, CH), Contassot; Emmanuel (Buschwiller, FR), French; Lars E. (Schweiz, CH), Gehrke; Samuel (Rapperswil, CH)
Assignee:	UNIVERSITAT ZURICH (Zurich, CH)
Application Number:	14/232,272
Patent Claims:	1. A method for the treatment of acne, comprising administering an effective amount of an inhibitor capable of binding to IL-1.beta., with a dissociation constant of at most 10.sup.-8 mol/l, wherein the inhibitor is selected from an IL-1.beta. antibody, and an antibody fragment. 2. The method according to claim 1, wherein the inhibitor is selected from the group consisting of canakinumab and gevokizumab and LY21899102.

Details for Patent 9,707,272

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	For Injection	125319	06/17/2009	⤷ Try a Trial	2031-07-12
Novartis Pharmaceuticals Corporation	ILARIS	canakinumab	Injection	125319	12/22/2016	⤷ Try a Trial	2031-07-12
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.